EICHOR
● Recruiting
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
Condition: Graft Versus Host Disease · Sponsor: Henry Ford Health System
About this study
So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic GVHD, progression-free survival , and overall survival
This description comes directly from the study's public registry record.
Talk to the study team
shatha farhan · 3137133910 · sfarhan1@hfhs.org
Always discuss trial participation with your own doctor first.
Locations (1)
| Henry Ford Hospital | Detroit, Michigan, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.